CY1106108T1 - Πεπτιδια και/ή πρωτεϊνες καθως και χρησιμοποιηση των ιδιων για την παρασκευη ενος θepαπευτικου και/ή προληπτικου φαρμακου - Google Patents

Πεπτιδια και/ή πρωτεϊνες καθως και χρησιμοποιηση των ιδιων για την παρασκευη ενος θepαπευτικου και/ή προληπτικου φαρμακου

Info

Publication number
CY1106108T1
CY1106108T1 CY20061100876T CY061100876T CY1106108T1 CY 1106108 T1 CY1106108 T1 CY 1106108T1 CY 20061100876 T CY20061100876 T CY 20061100876T CY 061100876 T CY061100876 T CY 061100876T CY 1106108 T1 CY1106108 T1 CY 1106108T1
Authority
CY
Cyprus
Prior art keywords
radical
peptides
proteins
therapeutic
preparation
Prior art date
Application number
CY20061100876T
Other languages
Greek (el)
English (en)
Inventor
Peter Petzelbauer
Original Assignee
Fibrex Medical Research & Development Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrex Medical Research & Development Gmbh filed Critical Fibrex Medical Research & Development Gmbh
Publication of CY1106108T1 publication Critical patent/CY1106108T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY20061100876T 2000-12-12 2006-06-27 Πεπτιδια και/ή πρωτεϊνες καθως και χρησιμοποιηση των ιδιων για την παρασκευη ενος θepαπευτικου και/ή προληπτικου φαρμακου CY1106108T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT20632000 2000-12-12
PCT/AT2001/000387 WO2002048180A2 (de) 2000-12-12 2001-12-07 Peptide und/oder proteine sowie verwendung desselben zur herstellung eines therapeutischen und/oder präventiven arzneimittels

Publications (1)

Publication Number Publication Date
CY1106108T1 true CY1106108T1 (el) 2011-06-08

Family

ID=3689750

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20061100876T CY1106108T1 (el) 2000-12-12 2006-06-27 Πεπτιδια και/ή πρωτεϊνες καθως και χρησιμοποιηση των ιδιων για την παρασκευη ενος θepαπευτικου και/ή προληπτικου φαρμακου
CY20091100574T CY1109107T1 (el) 2000-12-12 2009-05-29 Πεπτιδια και/ή πρωτεϊνες καθως και η χρησιμοποιηση τους για την παρασκευη ενος θεραπευτικου και/ή προληπτικου φαρμακου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20091100574T CY1109107T1 (el) 2000-12-12 2009-05-29 Πεπτιδια και/ή πρωτεϊνες καθως και η χρησιμοποιηση τους για την παρασκευη ενος θεραπευτικου και/ή προληπτικου φαρμακου

Country Status (30)

Country Link
US (4) US7271144B2 (cg-RX-API-DMAC7.html)
EP (2) EP1586586B1 (cg-RX-API-DMAC7.html)
JP (1) JP4181874B2 (cg-RX-API-DMAC7.html)
KR (1) KR100864069B1 (cg-RX-API-DMAC7.html)
CN (2) CN1518558B (cg-RX-API-DMAC7.html)
AT (2) ATE425184T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002221316A1 (cg-RX-API-DMAC7.html)
BG (1) BG107891A (cg-RX-API-DMAC7.html)
BR (1) BR0116122A (cg-RX-API-DMAC7.html)
CA (1) CA2430972C (cg-RX-API-DMAC7.html)
CY (2) CY1106108T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20031630A3 (cg-RX-API-DMAC7.html)
DE (2) DE50110182D1 (cg-RX-API-DMAC7.html)
DK (2) DK1586586T3 (cg-RX-API-DMAC7.html)
EA (1) EA005576B1 (cg-RX-API-DMAC7.html)
EE (1) EE200300283A (cg-RX-API-DMAC7.html)
ES (2) ES2323963T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20030564A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0401536A3 (cg-RX-API-DMAC7.html)
IL (2) IL156360A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03005218A (cg-RX-API-DMAC7.html)
NO (1) NO330767B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ550619A (cg-RX-API-DMAC7.html)
PL (2) PL209419B1 (cg-RX-API-DMAC7.html)
PT (2) PT1586586E (cg-RX-API-DMAC7.html)
SI (2) SI1586586T1 (cg-RX-API-DMAC7.html)
SK (1) SK7062003A3 (cg-RX-API-DMAC7.html)
WO (1) WO2002048180A2 (cg-RX-API-DMAC7.html)
YU (1) YU53803A (cg-RX-API-DMAC7.html)
ZA (1) ZA200304545B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1518558B (zh) 2000-12-12 2010-06-16 菲布雷克斯医疗研究及开发有限责任公司 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途
PT1691827E (pt) * 2004-06-25 2009-11-23 Fibrex Medical Res & Dev Gmbh Utilização de péptidos derivados da cadeia b beta de fibrinogénio humano para o tratamento do choque
FR2879604B1 (fr) * 2004-12-22 2010-08-13 Biomerieux Sa Peptides citrullines derives de la fibrine reconnus par des auto-anticorps specifiques de la polyarthrite rhumatoide, et leurs utilisations
AT502987A1 (de) 2005-12-23 2007-07-15 Fibrex Medical Res & Dev Gmbh Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
US7799758B2 (en) * 2006-02-23 2010-09-21 Ikaria Development Subsidiary Two, LLC Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
DK1987063T3 (da) * 2006-02-23 2010-01-04 Fibrex Medical Res & Dev Gmbh Peptider og peptidderivater, fremstilling deraf samt deres anvendelse til fremstilling af en terapeutisk og/eller præventivt aktiv farmaceutisk sammensætning
WO2007095659A1 (de) * 2006-02-23 2007-08-30 Fibrex Medical Research & Development Gmbh Peptide und peptid-derivate, herstellun derselben sowie deren verwendung zur herstellung eines therapeutisch und/oder präventiv wirkenden arzneimittels
FR2900657B1 (fr) 2006-05-03 2009-04-17 Univ Toulouse Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
WO2009038729A2 (en) 2007-09-17 2009-03-26 Regenerx Biopharmaceuticals, Inc. Compositions and methods utilizing fibrin beta chain fragments of the bbeta chain of fibrinogen
FR2908134B1 (fr) * 2007-12-04 2012-10-12 Univ Toulouse 3 Paul Sabatier Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
JP5410997B2 (ja) * 2008-01-31 2014-02-05 則行 川村 うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断
US20090286725A1 (en) * 2008-05-15 2009-11-19 Fibrex Medical Research & Development Gmbh Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
US8088890B2 (en) 2008-09-26 2012-01-03 Fibrex Medical Research & Development Gmbh Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2010043444A2 (en) * 2008-10-15 2010-04-22 Fibrex Medical Research & Development Gmbh Pharmaceutical preparation for the treatment and/or prevention of ischemia/reperfusion injury and the sequels thereof
US20100152832A1 (en) * 2008-12-12 2010-06-17 Medtronic Vascular, Inc. Apparatus and Methods for Treatment of Aneurysms With Fibrin Derived Peptide B-Beta
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
WO2017210539A1 (en) 2016-06-02 2017-12-07 University Of Maryland, Baltimore Compositions for inhibiting fibrin-vldl receptor-dependent inflammation and methods of treatment
EP3912679A1 (en) * 2020-05-19 2021-11-24 Johann Wolfgang Goethe-Universität Frankfurt am Main Bbeta-15-42 for the treatment of viral endothelitis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927916A (en) * 1984-04-23 1990-05-22 The General Hospital Corporation Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides
US5965107A (en) * 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
DE19729591A1 (de) * 1997-07-10 1999-02-11 Therasorb Medizinische Systeme Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen
FR2795735B1 (fr) * 1999-07-01 2001-09-07 Univ Toulouse Derives citrullines de la fibrine et leur utilisation pour le diagnostic ou le traitement de la polyarthrite rhumatoide
CN1518558B (zh) 2000-12-12 2010-06-16 菲布雷克斯医疗研究及开发有限责任公司 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途
US7201763B2 (en) * 2001-10-24 2007-04-10 Boston Scientific Scimed, Inc. Distal balloon waist material relief and method of manufacture

Also Published As

Publication number Publication date
KR100864069B1 (ko) 2008-10-16
US20090137464A1 (en) 2009-05-28
CY1109107T1 (el) 2014-07-02
SI1341819T1 (sl) 2006-10-31
US7811985B2 (en) 2010-10-12
EA200300678A1 (ru) 2003-10-30
PL209419B1 (pl) 2011-08-31
CZ20031630A3 (cs) 2003-10-15
DE50114771D1 (de) 2009-04-23
EP1341819B1 (de) 2006-06-14
US20040192596A1 (en) 2004-09-30
MXPA03005218A (es) 2004-12-03
EP1341819A2 (de) 2003-09-10
PL362924A1 (en) 2004-11-02
HUP0401536A2 (hu) 2004-11-29
PT1341819E (pt) 2006-10-31
ATE425184T1 (de) 2009-03-15
CN1518558A (zh) 2004-08-04
ZA200304545B (en) 2004-09-13
ES2266093T3 (es) 2007-03-01
EP1586586A2 (de) 2005-10-19
DK1341819T3 (da) 2006-10-16
SI1586586T1 (sl) 2009-08-31
US20070037749A1 (en) 2007-02-15
AU2002221316A1 (en) 2002-06-24
NO330767B1 (no) 2011-07-11
KR20030060988A (ko) 2003-07-16
HRP20030564A2 (en) 2005-06-30
EE200300283A (et) 2003-10-15
CN1518558B (zh) 2010-06-16
CA2430972C (en) 2014-08-05
ES2323963T3 (es) 2009-07-28
WO2002048180A3 (de) 2003-01-30
BG107891A (bg) 2004-08-31
NZ550619A (en) 2008-06-30
YU53803A (sh) 2006-03-03
US8067373B2 (en) 2011-11-29
JP2004527469A (ja) 2004-09-09
BR0116122A (pt) 2003-10-14
PL209752B1 (pl) 2011-10-31
PT1586586E (pt) 2010-05-28
NO20032656D0 (no) 2003-06-12
EP1586586B1 (de) 2009-03-11
IL156360A0 (en) 2004-01-04
DE50110182D1 (de) 2006-07-27
EA005576B1 (ru) 2005-04-28
US7271144B2 (en) 2007-09-18
US7494973B2 (en) 2009-02-24
SK7062003A3 (en) 2003-11-04
HK1084400A1 (zh) 2006-07-28
US20090088384A1 (en) 2009-04-02
NO20032656L (no) 2003-06-12
IL156360A (en) 2012-12-31
EP1586586A3 (de) 2006-03-29
CN101676299A (zh) 2010-03-24
HUP0401536A3 (en) 2008-09-29
JP4181874B2 (ja) 2008-11-19
CA2430972A1 (en) 2002-06-20
DK1586586T3 (da) 2009-06-29
ATE329614T1 (de) 2006-07-15
WO2002048180A2 (de) 2002-06-20

Similar Documents

Publication Publication Date Title
CY1109107T1 (el) Πεπτιδια και/ή πρωτεϊνες καθως και η χρησιμοποιηση τους για την παρασκευη ενος θεραπευτικου και/ή προληπτικου φαρμακου
ES2178000T3 (es) Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
ES2181006T3 (es) Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion.
ATE183514T1 (de) Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten
BR9812469A (pt) Composições farmacêuticas contendo proteina de plasma
ATE280826T1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
EA200000652A1 (ru) Кристаллы глюкагоноподобного пептида 1
GR3026658T3 (en) Hydrazino-type radionuclide chelators having an n 3?s configuration
UA65561A (en) Therapeutic agent for lymphatic tumors
BR9910639A (pt) Drogas anti-angiogênicas compreendendo peptìdeo
AU2001264515A1 (en) Melphalan derivatives and their use as cancer chemotherapeutic drugs
ES2179064T3 (es) Procedimiento para la preparacion de lipoproteina reconstituida.
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
ES2066510T3 (es) Nuevos polipeptidos con afinidad para lipopolisacaridos y sus usos.
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
BR9809103A (pt) Forma farmacêutica estável de administração para peptìdeos, proteìnas e ácidos nucléicos
ATE355302T1 (de) N-substituierte d-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation
Bonnet et al. Synthesis by chemoselective ligation and biological evaluation of novel cell-permeable PKC-ζ pseudosubstrate lipopeptides
IL173969A0 (en) Use of peptides derived from the a alpha or b beta chain of human of human fibrinogen for the treatment of shock
ES2150421T3 (es) Nuevos conjugados, consistentes en una glicoproteina y una sustancia que se fija a acidos nucleicos.
RU2215005C2 (ru) Регуляторные/развернутые пептиды эзрина
DK1189615T3 (da) Endoparasiticid synergistisk kombination indeholdende cykliske depsipeptider og piperaziner
GB9604518D0 (en) Novel compounds
DE60323164D1 (de) Arginin/lysin-angereicherte peptide